AstraZeneca strengthens oncology with Definiens buy, Pharmacyclics deal
This article was originally published in Scrip
Executive Summary
AstraZeneca is consolidating its position in oncology R&D by buying the private tumor biomarker company Definiens and collaborating with Pharmacyclics to test its novel targeted agent Imbruvica (ibrutinib) with AstraZeneca's anti-PD-L1 product candidate.